세계의 순환종양세포 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)

The global market for Circulating Tumor Cells was estimated to be worth US$ 2291 million in 2024 and is forecast to a readjusted size of US$ 8259 million by 2031 with a CAGR of 20.4% during the forecast period 2025-2031.

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

The circulating tumor cells (CTC) market is gaining significant traction due to its critical role in cancer detection, prognosis, and treatment monitoring. CTCs are cancer cells that have shed from the primary tumor into the bloodstream, offering a minimally invasive method for liquid biopsy. This technology is becoming increasingly important as it enables early detection, real-time disease monitoring, and personalized therapy selection without the need for invasive tissue biopsies. Key drivers include rising cancer incidence globally, advancements in microfluidics and next-generation sequencing, and growing demand for precision medicine solutions.

The market is witnessing innovations in CTC detection and isolation technologies, such as immunomagnetic separation, microfluidic devices, and PCR-based methods, which enhance accuracy and sensitivity. Pharmaceutical and diagnostic companies are heavily investing in research collaborations and clinical trials to integrate CTC analysis into cancer care protocols. Moreover, the integration of artificial intelligence and bioinformatics for interpreting complex CTC data is creating new opportunities for diagnostic and therapeutic advancements. As healthcare systems prioritize early cancer diagnosis and personalized treatment approaches, the adoption of CTC-based diagnostics is expected to grow significantly across clinical and research applications.

This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Circulating Tumor Cells by region & country, by Type, and by Application.

The Circulating Tumor Cells market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells.

Market Segmentation

By Company

• Menarini-Silicon Biosystems
• Qiagen (Adnagen)
• Advanced Cell Diagnostics
• ApoCell
• Epic Sciences
• Greiner Bio-one GmbH
• Cynvenio
• SurExamBio-Tech
• Fluxion Biosciences
• Ikonisys
• Hangzhou Watson Biotech
• Biocept
• CytoTrack
• Guangzhou Wondfo Biotech
• Celsee
• Clearbridge Biomedics
• ANGLE plc

Segment by Type

• CTC Enrichment
• CTC Detection
• CTC Analysis

Segment by Application

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Lung Cancer
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Circulating Tumor Cells company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Circulating Tumor Cells in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Circulating Tumor Cells in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Circulating Tumor Cells Product Introduction
• 1.2 Global Circulating Tumor Cells Market Size Forecast (2020-2031)
• 1.3 Circulating Tumor Cells Market Trends & Drivers
  • 1.3.1 Circulating Tumor Cells Industry Trends
  • 1.3.2 Circulating Tumor Cells Market Drivers & Opportunity
  • 1.3.3 Circulating Tumor Cells Market Challenges
  • 1.3.4 Circulating Tumor Cells Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Circulating Tumor Cells Players Revenue Ranking (2024)
• 2.2 Global Circulating Tumor Cells Revenue by Company (2020-2025)
• 2.3 Key Companies Circulating Tumor Cells Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Circulating Tumor Cells Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Circulating Tumor Cells
• 2.6 Circulating Tumor Cells Market Competitive Analysis
  • 2.6.1 Circulating Tumor Cells Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Circulating Tumor Cells Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 CTC Enrichment
  • 3.1.2 CTC Detection
  • 3.1.3 CTC Analysis
• 3.2 Global Circulating Tumor Cells Sales Value by Type
  • 3.2.1 Global Circulating Tumor Cells Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Circulating Tumor Cells Sales Value, by Type (2020-2031)
  • 3.2.3 Global Circulating Tumor Cells Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Breast Cancer
  • 4.1.2 Prostate Cancer
  • 4.1.3 Colorectal Cancer
  • 4.1.4 Lung Cancer
  • 4.1.5 Others
• 4.2 Global Circulating Tumor Cells Sales Value by Application
  • 4.2.1 Global Circulating Tumor Cells Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Circulating Tumor Cells Sales Value, by Application (2020-2031)
  • 4.2.3 Global Circulating Tumor Cells Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Circulating Tumor Cells Sales Value by Region
  • 5.1.1 Global Circulating Tumor Cells Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Circulating Tumor Cells Sales Value by Region (2020-2025)
  • 5.1.3 Global Circulating Tumor Cells Sales Value by Region (2026-2031)
  • 5.1.4 Global Circulating Tumor Cells Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Circulating Tumor Cells Sales Value, 2020-2031
  • 5.2.2 North America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Circulating Tumor Cells Sales Value, 2020-2031
  • 5.3.2 Europe Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Circulating Tumor Cells Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Circulating Tumor Cells Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Circulating Tumor Cells Sales Value, 2020-2031
  • 5.5.2 South America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Circulating Tumor Cells Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Circulating Tumor Cells Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Circulating Tumor Cells Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Circulating Tumor Cells Sales Value, 2020-2031
  • 6.3.2 United States Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Circulating Tumor Cells Sales Value, 2020-2031
  • 6.4.2 Europe Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Circulating Tumor Cells Sales Value, 2020-2031
  • 6.5.2 China Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Circulating Tumor Cells Sales Value, 2020-2031
  • 6.6.2 Japan Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Circulating Tumor Cells Sales Value, 2020-2031
  • 6.7.2 South Korea Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Circulating Tumor Cells Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Circulating Tumor Cells Sales Value, 2020-2031
  • 6.9.2 India Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Circulating Tumor Cells Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Menarini-Silicon Biosystems
  • 7.1.1 Menarini-Silicon Biosystems Profile
  • 7.1.2 Menarini-Silicon Biosystems Main Business
  • 7.1.3 Menarini-Silicon Biosystems Circulating Tumor Cells Products, Services and Solutions
  • 7.1.4 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Menarini-Silicon Biosystems Recent Developments
• 7.2 Qiagen (Adnagen)
  • 7.2.1 Qiagen (Adnagen) Profile
  • 7.2.2 Qiagen (Adnagen) Main Business
  • 7.2.3 Qiagen (Adnagen) Circulating Tumor Cells Products, Services and Solutions
  • 7.2.4 Qiagen (Adnagen) Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Qiagen (Adnagen) Recent Developments
• 7.3 Advanced Cell Diagnostics
  • 7.3.1 Advanced Cell Diagnostics Profile
  • 7.3.2 Advanced Cell Diagnostics Main Business
  • 7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells Products, Services and Solutions
  • 7.3.4 Advanced Cell Diagnostics Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Advanced Cell Diagnostics Recent Developments
• 7.4 ApoCell
  • 7.4.1 ApoCell Profile
  • 7.4.2 ApoCell Main Business
  • 7.4.3 ApoCell Circulating Tumor Cells Products, Services and Solutions
  • 7.4.4 ApoCell Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.4.5 ApoCell Recent Developments
• 7.5 Epic Sciences
  • 7.5.1 Epic Sciences Profile
  • 7.5.2 Epic Sciences Main Business
  • 7.5.3 Epic Sciences Circulating Tumor Cells Products, Services and Solutions
  • 7.5.4 Epic Sciences Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Epic Sciences Recent Developments
• 7.6 Greiner Bio-one GmbH
  • 7.6.1 Greiner Bio-one GmbH Profile
  • 7.6.2 Greiner Bio-one GmbH Main Business
  • 7.6.3 Greiner Bio-one GmbH Circulating Tumor Cells Products, Services and Solutions
  • 7.6.4 Greiner Bio-one GmbH Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Greiner Bio-one GmbH Recent Developments
• 7.7 Cynvenio
  • 7.7.1 Cynvenio Profile
  • 7.7.2 Cynvenio Main Business
  • 7.7.3 Cynvenio Circulating Tumor Cells Products, Services and Solutions
  • 7.7.4 Cynvenio Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.7.5 Cynvenio Recent Developments
• 7.8 SurExamBio-Tech
  • 7.8.1 SurExamBio-Tech Profile
  • 7.8.2 SurExamBio-Tech Main Business
  • 7.8.3 SurExamBio-Tech Circulating Tumor Cells Products, Services and Solutions
  • 7.8.4 SurExamBio-Tech Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.8.5 SurExamBio-Tech Recent Developments
• 7.9 Fluxion Biosciences
  • 7.9.1 Fluxion Biosciences Profile
  • 7.9.2 Fluxion Biosciences Main Business
  • 7.9.3 Fluxion Biosciences Circulating Tumor Cells Products, Services and Solutions
  • 7.9.4 Fluxion Biosciences Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Fluxion Biosciences Recent Developments
• 7.10 Ikonisys
  • 7.10.1 Ikonisys Profile
  • 7.10.2 Ikonisys Main Business
  • 7.10.3 Ikonisys Circulating Tumor Cells Products, Services and Solutions
  • 7.10.4 Ikonisys Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.10.5 Ikonisys Recent Developments
• 7.11 Hangzhou Watson Biotech
  • 7.11.1 Hangzhou Watson Biotech Profile
  • 7.11.2 Hangzhou Watson Biotech Main Business
  • 7.11.3 Hangzhou Watson Biotech Circulating Tumor Cells Products, Services and Solutions
  • 7.11.4 Hangzhou Watson Biotech Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.11.5 Hangzhou Watson Biotech Recent Developments
• 7.12 Biocept
  • 7.12.1 Biocept Profile
  • 7.12.2 Biocept Main Business
  • 7.12.3 Biocept Circulating Tumor Cells Products, Services and Solutions
  • 7.12.4 Biocept Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.12.5 Biocept Recent Developments
• 7.13 CytoTrack
  • 7.13.1 CytoTrack Profile
  • 7.13.2 CytoTrack Main Business
  • 7.13.3 CytoTrack Circulating Tumor Cells Products, Services and Solutions
  • 7.13.4 CytoTrack Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.13.5 CytoTrack Recent Developments
• 7.14 Guangzhou Wondfo Biotech
  • 7.14.1 Guangzhou Wondfo Biotech Profile
  • 7.14.2 Guangzhou Wondfo Biotech Main Business
  • 7.14.3 Guangzhou Wondfo Biotech Circulating Tumor Cells Products, Services and Solutions
  • 7.14.4 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.14.5 Guangzhou Wondfo Biotech Recent Developments
• 7.15 Celsee
  • 7.15.1 Celsee Profile
  • 7.15.2 Celsee Main Business
  • 7.15.3 Celsee Circulating Tumor Cells Products, Services and Solutions
  • 7.15.4 Celsee Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.15.5 Celsee Recent Developments
• 7.16 Clearbridge Biomedics
  • 7.16.1 Clearbridge Biomedics Profile
  • 7.16.2 Clearbridge Biomedics Main Business
  • 7.16.3 Clearbridge Biomedics Circulating Tumor Cells Products, Services and Solutions
  • 7.16.4 Clearbridge Biomedics Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.16.5 Clearbridge Biomedics Recent Developments
• 7.17 ANGLE plc
  • 7.17.1 ANGLE plc Profile
  • 7.17.2 ANGLE plc Main Business
  • 7.17.3 ANGLE plc Circulating Tumor Cells Products, Services and Solutions
  • 7.17.4 ANGLE plc Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
  • 7.17.5 ANGLE plc Recent Developments

8 Industry Chain Analysis

• 8.1 Circulating Tumor Cells Industrial Chain
• 8.2 Circulating Tumor Cells Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Circulating Tumor Cells Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Circulating Tumor Cells Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer